106 related articles for article (PubMed ID: 12815163)
1. Positive allosteric modulator of the human 5-HT2C receptor.
Im WB; Chio CL; Alberts GL; Dinh DM
Mol Pharmacol; 2003 Jul; 64(1):78-84. PubMed ID: 12815163
[TBL] [Abstract][Full Text] [Related]
2. Exploration of synthetic approaches and pharmacological evaluation of PNU-69176E and its stereoisomer as 5-HT2C receptor allosteric modulators.
Ding C; Bremer NM; Smith TD; Seitz PK; Anastasio NC; Cunningham KA; Zhou J
ACS Chem Neurosci; 2012 Jul; 3(7):538-45. PubMed ID: 22860223
[TBL] [Abstract][Full Text] [Related]
3. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
Cussac D; Newman-Tancredi A; Quentric Y; Carpentier N; Poissonnet G; Parmentier JG; Goldstein S; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):242-52. PubMed ID: 11882920
[TBL] [Abstract][Full Text] [Related]
4. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor.
Brüss M; Kiel S; Bönisch H; Kostanian A; Göthert M
Neurochem Int; 2005 Aug; 47(3):196-203. PubMed ID: 15896881
[TBL] [Abstract][Full Text] [Related]
5. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
[TBL] [Abstract][Full Text] [Related]
6. Allosteric modulation of the human 5-HT(7A) receptor by lipidic amphipathic compounds.
Alberts GL; Chio CL; Im WB
Mol Pharmacol; 2001 Dec; 60(6):1349-55. PubMed ID: 11723242
[TBL] [Abstract][Full Text] [Related]
7. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
[TBL] [Abstract][Full Text] [Related]
8. Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA.
López-Giménez JF; Mengod G; Palacios JM; Vilaró MT
Synapse; 2001 Oct; 42(1):12-26. PubMed ID: 11668587
[TBL] [Abstract][Full Text] [Related]
9. Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat.
Morán A; Ortiz de Urbina AV; Martín ML; García M; Rodriguez-Barbero A; Dorado F; San Román L
Eur J Pharmacol; 2008 Sep; 592(1-3):133-7. PubMed ID: 18644367
[TBL] [Abstract][Full Text] [Related]
10. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
11. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
Oz M; Zhang L; Rotondo A; Sun H; Morales M
Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
[TBL] [Abstract][Full Text] [Related]
12. Intracellular cAMP and calcium signaling by serotonin in mouse cumulus-oocyte complexes.
Amireault P; Dubé F
Mol Pharmacol; 2005 Dec; 68(6):1678-87. PubMed ID: 16131615
[TBL] [Abstract][Full Text] [Related]
13. New 5-hydroxytryptamine(1A) receptor ligands containing a norbornene nucleus: synthesis and in vitro pharmacological evaluation.
Fiorino F; Perissutti E; Severino B; Santagada V; Cirillo D; Terracciano S; Massarelli P; Bruni G; Collavoli E; Renner C; Caliendo G
J Med Chem; 2005 Aug; 48(17):5495-503. PubMed ID: 16107148
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus.
Fiorino F; Severino B; De Angelis F; Perissutti E; Magli E; Frecentese F; Esposito A; Massarelli P; Nencini C; Viti B; Santagada V; Caliendo G
Pharmazie; 2009 Sep; 64(9):555-64. PubMed ID: 19827295
[TBL] [Abstract][Full Text] [Related]
15. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats.
Liu FY; Xing GG; Qu XX; Xu IS; Han JS; Wan Y
J Pharmacol Exp Ther; 2007 Jun; 321(3):1046-53. PubMed ID: 17329553
[TBL] [Abstract][Full Text] [Related]
16. N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function.
Urwyler S; Pozza MF; Lingenhoehl K; Mosbacher J; Lampert C; Froestl W; Koller M; Kaupmann K
J Pharmacol Exp Ther; 2003 Oct; 307(1):322-30. PubMed ID: 12954816
[TBL] [Abstract][Full Text] [Related]
17. Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus.
Giannaccini G; Betti L; Pirone A; Palego L; Fabiani O; Fabbrini L; Mascia G; Giusti L; Macchia M; Giusiani M; Martini C; Lucacchini A
Neurochem Int; 2007 Dec; 51(8):496-506. PubMed ID: 17602794
[TBL] [Abstract][Full Text] [Related]
18. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2.
Schaffhauser H; Rowe BA; Morales S; Chavez-Noriega LE; Yin R; Jachec C; Rao SP; Bain G; Pinkerton AB; Vernier JM; Bristow LJ; Varney MA; Daggett LP
Mol Pharmacol; 2003 Oct; 64(4):798-810. PubMed ID: 14500736
[TBL] [Abstract][Full Text] [Related]
20. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
